Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jun 8;2(6):550–571. doi: 10.1038/s44161-023-00278-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023, corrected publication 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 8 — A. viSNE plot of major cell types in healthy PBMC defined based on canonical expression patterns. B. The phosphorylation signaling of AKT, LCK, SRC was visualized across this immune map in response to atheroplasma (athero) vs atheroplasma + saracatinib 10 µM (athero+sara), or no stimulation (no plasma); n = 4 biologically independent samples/condition, males=1. C. Dot plots show the effect of atheroplasma (athero) vs atheroplasma + saracatinib 10 µM (athero+sara), or no stimulation (no plasma) on the phosphorylation of AKT, LCK, SRC in CD14⁺ monocytes and CD1c⁺ DCs, n = 4 biologically independent samples/condition, males=1. P values were determined by one-way ANOVA with Tukey’s post hoc test across all groups. D. Dot plots show the effect of atheroplasma (athero) vs atheroplasma + saracatinib 10 µM (athero+sara), or no stimulation (no plasma) on protein levels of AKT, LCK, SRC in CD14⁺ monocytes; n = 4 biologically independent samples/condition, males=1. P values were determined by one-way ANOVA with Tukey’s post hoc test across all groups. E. Dot plots show the effect of atheroplasma (athero) vs atheroplasma + saracatinib 10 µM (athero+sara), or no stimulation (no plasma) on total protein levels of AKT, LCK, SRC in CD1c⁺ DCs; n = 4 biologically independent samples/condition, males=1. P values were determined by one-way ANOVA with Tukey’s post hoc test across all groups. F. Dot plots show the effect of atheroplasma (athero) vs atherosplasma + saracatinib 10 µM (athero+sara), or no stimulation (no plasma) on phosphorylation and total protein levels of AKT, LCK, SRC in CD16+ monocytes, CD4 + T cells, CD8 + T cells; n = 4 biologically independent samples/condition, males=1. P values were determined by one-way ANOVA with Tukey’s post hoc test across all groups. G. Dot plots show the effect of atheroplasma (athero) vs atheroplasma + saracatinib 10 µM (athero+sara), or no stimulation (no plasma) on total protein levels of AKT, LCK, SRC in CD16+ monocytes, CD4 + T cells, CD8 + T cells; n = 4 biologically independent samples/condition, males=1. P values were determined by one-way ANOVA with Tukey’s post hoc test across all groups.